Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Common Equity (2022 - 2025)

NewAmsterdam Pharma's Common Equity history spans 4 years, with the latest figure at $683.4 million for Q4 2025.

  • For Q4 2025, Common Equity fell 9.78% year-over-year to $683.4 million; the TTM value through Dec 2025 reached $683.4 million, down 9.78%, while the annual FY2025 figure was $683.4 million, 9.78% down from the prior year.
  • Common Equity for Q4 2025 was $683.4 million at NewAmsterdam Pharma, down from $728.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $778.5 million in Q2 2025 and bottomed at $288.4 million in Q4 2023.
  • The 4-year median for Common Equity is $411.8 million (2024), against an average of $522.3 million.
  • The largest annual shift saw Common Equity tumbled 41.66% in 2023 before it soared 162.66% in 2024.
  • A 4-year view of Common Equity shows it stood at $494.3 million in 2022, then plummeted by 41.66% to $288.4 million in 2023, then skyrocketed by 162.66% to $757.5 million in 2024, then decreased by 9.78% to $683.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Common Equity are $683.4 million (Q4 2025), $728.1 million (Q3 2025), and $778.5 million (Q2 2025).